What is Open Book Extracts?
Founded in 2018 and headquartered in Roxboro, NC, Open Book Extracts (OBX) operates as a cGMP-certified manufacturer specializing in premium plant-based cannabinoid products. The company positions itself as the industry's 'true north,' emphasizing premium product delivery, exceptional service, and unparalleled transparency. OBX maintains comprehensive control over its entire supply chain, leveraging a state-of-the-art extraction campus situated near North Carolina's Research Triangle. Its proprietary refinement and conversion methods are supported by a growing intellectual property portfolio, and its team comprises Ph.D. chemists and seasoned business leaders. This integrated approach makes OBX a trusted partner for global brands aiming to enter the cannabinoid marketplace. The company also extends its reach internationally with OBX Asia, based in Hong Kong, providing strategic guidance and localized support to its Asian clientele.
How much funding has Open Book Extracts raised?
Open Book Extracts has raised a total of $11.5M across 1 funding round:
Series B
$11.5M
Series B (2021): $11.5M with participation from Nortecapital and KEY Investment Partners
Key Investors in Open Book Extracts
Nortecapital
Nortecapital is an investment firm that has participated in Open Book Extracts' Series B funding round. Further details on their specific investment focus are not provided.
KEY Investment Partners
KEY Investment Partners is a U.S.-based private equity and venture capital firm focused on the cannabis industry. It invests in high-growth companies across the cannabis value chain, providing both capital and strategic guidance to help businesses scale in a rapidly evolving regulatory market.
What's next for Open Book Extracts?
With the recent influx of enterprise-level capital, Open Book Extracts is poised for accelerated growth and innovation. The company's strategic focus on controlling the full supply chain, from cultivation to refinement, combined with its investment in proprietary technologies and a robust IP portfolio, positions it favorably for scaling operations and expanding its market share. Future initiatives will likely involve enhancing its product offerings, broadening its global distribution network, and further solidifying its reputation for transparency and quality in the rapidly evolving cannabinoid industry. The company's commitment to research and development, backed by its team of expert chemists, suggests a continued pipeline of innovative solutions for its brand partners.
See full Open Book Extracts company page
